Back to homepageOur expertise in microbiology and molecular biology enables us to support the development of your candidates that contribute to the health of domestic animals or livestock through preventive or curative approaches. To ensure that your projects are carried out under the best possible conditions, our team will support you throughout your development, from the research phases to the monitoring of animal studies.
Who are you?
What are you looking for?
In the context of the development of your drug candidates aimed at improving animal health, you are seeking an in vitro services provider in microbiology and molecular biology to support your projects in the design and enhancement of products at all stages. Smaltis is the ideal company to meet your needs, offering high scientific expertise and a customized approach.
The products you plan to develop
- Antibiotics
- Antifungals
- Antimicrobial peptides
- Antibacterial antibodies
- Vaccine components
- Other molecules for anti-infectious purposes
- Other compounds acting on animal health through the microbiome
- Disinfectant products
The approaches you work on
Are you working on the anti-infectious axis, on modulating a microbiome, or on developing compounds used for animal vaccination? Whatever strategy you employ to bring benefits to animal health, the Smaltis team, along with its expertise, knowledge, and technologies, is at your disposal to facilitate and successfully execute your projects.
Our offer
Antimicrobials
Let's fight infectious diseases together
Microbiota
Let's explore the health potential of microbiota together
Bioproduction
Let's build your bioproduction tools and prepare your microbial products
Genomics
Let's study the genomic and transcriptomic aspects of your projects
Strain collections
Strain collections available for your projects
At what stage are you?
| DEVELOPMENT STAGES |
1
RESEARCH & SELECTION |
2
PROOF OF CONCEPT/EFFICACY |
3
BIOPROCESSES |
4
ANIMAL STUDIES |
| OUR SERVICES |
Screening of candidates, |
Understanding of action mechanisms, |
Development and optimization of bioprocesses, |
Support for animal studies through in vitro monitoring of samples, |
Why choose Smaltis?
Our services and support enable you to supply, enhance, and secure your data within a rigorous scientific framework. We have been working for several years on various projects in animal health, and our teams of scientists are capable of discussing your objectives and recommending the most suitable and relevant manipulations for your needs. You can rely on Smaltis for complete project management, adaptation to your requirements, and guaranteed traceability of the experiments conducted.
Get in touch!
Delphine GALLAND
Head of Preclinical Clinical Studies
VETOQUINOL
For the past 10 years, we have regularly turned to Smaltis for their services and expertise in microbiology, cellular biology, and molecular biology. The entrusted work focused on evaluating the efficacy and safety of various products related to infectious diseases. The smoothness of our interactions, the responsiveness of the entire team, and their adaptation to our regulatory requirements have allowed us to advance our research projects optimally. The trust we have placed in Smaltis over these 10 years has led us to include this provider among our preferred contacts.
Jérôme SCHMEISSER and Christelle IACONIS
Biology lab manager
and Scientist
DSM-FIRMENICH
In the context of our developments in animal health dietary supplements, we turned to SMALTIS to assess the impact of our products on the expression of genes of interest in different tissues. The molecular biology expertise of SMALTIS allows us to rely on this laboratory, whose qualitative results provide us with robust and reliable data. We also benefit from constructive exchanges with their teams to progress together throughout the project. SMALTIS thus constitutes a true extension of our R&D department, allowing us to focus on our own expertise while relying on this partner with whom we will continue to collaborate.
Pierre BELICHARD
CEO
ENTEROME
As part of the development of our candidate EB8018 designed to block bacteria expressing virulence factor FimH (a key inducer of the inflammatory cascade of the intestine, particularly in patients with Crohn disease), we have successively called upon the services of SMALTIS. In the preclinical phase, they first quantified in vitro the adhesion and invasion capacities of a collection of strains isolated from patients on a model of intestinal cell infection and then evaluated the impact of our molecule on these strains. The quality of the work performed, the level of expertise of the team combined with the ability to listen and adapt, led us to include SMALTIS as a service provider in our Phase 1b clinical study. The team developed a customized procedure to isolate and dissociate bacteria called "adherent" and "invasive" in intestinal biopsies, and then demonstrated the action of our EB8018 compound on these strains. SMALTIS continues to support the development of EB8018 in a phase 2a clinical trial.
Romain DAILLERE
Head of Preclinical Research - Co-founder
EVERIMMUNE
As part of the Oncobax®-AK project and the development of Live Biotherapeutic Products to potentiate the efficacy of cancer immunotherapies, we called upon Smaltis' services to characterize one of our candidate bacterial strains. The objective was to provide a complete file to the regulatory authorities regarding the characteristics of the strain, before initiating clinical studies. The Smaltis team worked hard to develop the protocols and test conditions necessary to determine the specificities of the strain of interest. The rigor shown by Smaltis' researchers, the quality and detail of the data transmitted, as well as the scientific relevance of the various characterization tests, allowed us to meet the regulatory requirements and to initiate the clinical trials with confidence. We are delighted to have collaborated with Smaltis.